Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors
07 Julio 2021 - 6:00AM
Business Wire
Sema4, a patient-centered health intelligence company leveraging
AI and machine learning to derive data-driven insights, today
announced the appointment of renowned executive Jason Ryan to its
Board of Directors. Mr. Ryan will begin serving on Sema4’s Board of
Directors upon his official appointment after Sema4 closes its
previously announced business combination with CM Life Sciences
(Nasdaq: CMLF), a special purpose acquisition company.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210707005228/en/
Jason Ryan (Photo: Business Wire)
Mr. Ryan most recently served as Chief Operating and Financial
Officer of Magenta Therapeutics (Nasdaq: MGTA), a biotechnology
company focused on developing novel medicines for patients with
autoimmune diseases and blood cancers. Prior to that, he was Chief
Financial Officer of Foundation Medicine, a molecular information
company, helping lead the business through early development, its
initial public offering, subsequent growth into a global commercial
organization, and ultimately its acquisition by Roche Holdings
(Nasdaq: RHHBY). Previously, Mr. Ryan led the finance and strategic
planning functions of several other high growth life science
companies.
“Jason brings to Sema4 outstanding leadership experience in the
life sciences and biotechnology sectors, and an impressive
background in finance and scaling businesses,” said Eric Schadt,
PhD, Founder and Chief Executive Officer of Sema4. “We expect that
Jason will be an invaluable addition to Sema4 as we transition to
becoming a publicly traded company, and we are delighted to have
the opportunity to leverage his expertise in support of our mission
to advance healthcare through data-driven insights.”
In addition to Sema4, Mr. Ryan currently serves on the board of
directors of Singular Genomics (Nasdaq: OMIC) and previously served
on the board of directors of ArcherDX, Inc. (acquired by Invitae
(NYSE: NVTA)). He began his career at Deloitte & Touche where
he earned a CPA, and received a B.A. in Economics from Bates
College and an M.B.A. from Babson College.
“Sema4 has built a unique data ecosystem and platform to drive
precision medicine into the standard of care,” said Mr. Ryan. “I’m
thrilled to join Sema4’s Board of Directors at such an exciting
time for the company. I look forward to working with the team to
help us further improve the diagnosis, treatment, and prevention of
disease.”
Mr. Ryan will be one of four new members of Sema4’s Board of
Directors after the company completes its business combination with
CM Life Sciences. Mr. Ryan joins the previously announced additions
of Nat Turner, co-founder of Flatiron Health (a Roche company),
Emily Leproust, Chief Executive Officer of Twist Biosciences
(Nasdaq: TWST), and Eli Casdin, Chief Investment Officer of Casdin
Capital.
About Sema4
Sema4 is a patient-centered health intelligence company
dedicated to advancing healthcare through data-driven insights.
Sema4 is transforming healthcare by applying AI and machine
learning to multidimensional, longitudinal clinical and genomic
data to build dynamic models of human health and defining optimal,
individualized health trajectories. Centrellis™, our innovative
health intelligence platform, is enabling us to generate a more
complete understanding of disease and wellness and to provide
science-driven solutions to the most pressing medical needs. Sema4
believes that patients should be treated as partners, and that data
should be shared for the benefit of all.
For more information, please visit sema4.com and connect with
Sema4 on Twitter, LinkedIn, Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210707005228/en/
Radley Moss radley.moss@sema4.com
CM Life Sciences (NASDAQ:CMLF)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CM Life Sciences (NASDAQ:CMLF)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024